This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Apogee Therapeutics, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Kenneth Evan Thompson: Innovator in Antibody Development
Introduction
Kenneth Evan Thompson is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target interleukin 13 (IL-13). His work has implications for treating various inflammatory diseases.
Latest Patents
Kenneth holds a patent for "Antibodies that bind interleukin 13 and methods of use." This patent describes novel and improved antibodies that bind IL-13 and outlines methods for inhibiting its biological activity. The patent also details pharmaceutical compositions that include these anti-IL-13 antibodies, which can be utilized in the treatment of inflammatory diseases associated with elevated levels of IL-13 and/or IgE.
Career Highlights
Kenneth is currently associated with Apogee Therapeutics, Inc., where he continues to advance research in therapeutic antibodies. His innovative work has positioned him as a key figure in the biotechnology sector.
Collaborations
Throughout his career, Kenneth has collaborated with esteemed colleagues such as Hussam H Shaheen and Peter Harwin. These partnerships have further enhanced the impact of his research and development efforts.
Conclusion
Kenneth Evan Thompson's contributions to antibody development represent a significant advancement in the treatment of inflammatory diseases. His innovative approach and dedication to research continue to influence the field of biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile